07:57 AM EDT, 09/17/2024 (MT Newswires) -- BridgeBio Pharma ( BBIO ) said Tuesday that the US Food and Drug Administration has granted Breakthrough Therapy Designation to oral infigratinib, which the biopharmaceutical company is developing to treat children with achondroplasia.
Shares of BridgeBio Pharma ( BBIO ) were up 1.8% in recent Tuesday premarket activity.
Price: 26.75, Change: +0.56, Percent Change: +2.14